Table of Contents
2019-2024 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Report (Status and Outlook)
1 Scope of the Report
1.1 Market Introduction
1.2 Research Objectives
1.3 Years Considered
1.4 Market Research Methodology
1.5 Economic Indicators
1.6 Currency Considered
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size 2014-2024
2.1.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size CAGR by Region
2.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Segment by Type
2.2.1 Pain Management Drugs
2.2.2 Corticosteroids
2.2.3 Prednisone
2.2.4 Deflazacort
2.2.5 Others
2.3 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type
2.3.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Market Share by Type (2014-2019)
2.3.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate by Type (2014-2019)
2.4 Duchenne Muscular Dystrophy (DMD) Therapeutics Segment by Application
2.4.1 Hospitals
2.4.2 Clinics
2.4.3 Home Care
2.5 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application
2.5.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Market Share by Application (2014-2019)
2.5.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate by Application (2014-2019)
3 Global Duchenne Muscular Dystrophy (DMD) Therapeutics by Players
3.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Market Share by Players
3.1.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Players (2017-2019)
3.1.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Market Share by Players (2017-2019)
3.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) (2017-2019)
3.4 New Products and Potential Entrants
3.5 Mergers and Acquisitions, Expansion
4 Duchenne Muscular Dystrophy (DMD) Therapeutics by Regions
4.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Regions
4.2 Americas Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth
4.3 APAC Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth
4.4 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth
4.5 Middle East and Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth
5 Americas
5.1 Americas Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Countries
5.2 Americas Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type
5.3 Americas Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Key Economic Indicators of Few Americas Countries
6 APAC
6.1 APAC Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Countries
6.2 APAC Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type
6.3 APAC Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 Key Economic Indicators of Few APAC Countries
7 Europe
7.1 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics by Countries
7.2 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type
7.3 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
7.9 Spain
7.10 Key Economic Indicators of Few Europe Countries
8 Middle East and Africa
8.1 Middle East and Africa Duchenne Muscular Dystrophy (DMD) Therapeutics by Countries
8.2 Middle East and Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type
8.3 Middle East and Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers and Impact
9.1.1 Growing Demand from Key Regions
9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends
10 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Forecast
10.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Forecast (2019-2024)
10.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Forecast by Regions
10.2.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Forecast by Regions (2019-2024)
10.2.2 Americas Market Forecast
10.2.3 APAC Market Forecast
10.2.4 Europe Market Forecast
10.2.5 Middle East and Africa Market Forecast
10.3 Americas Forecast by Countries
10.3.1 United States Market Forecast
10.3.2 Canada Market Forecast
10.3.3 Mexico Market Forecast
10.3.4 Brazil Market Forecast
10.4 APAC Forecast by Countries
10.4.1 China Market Forecast
10.4.2 Japan Market Forecast
10.4.3 Korea Market Forecast
10.4.4 Southeast Asia Market Forecast
10.4.5 India Market Forecast
10.4.6 Australia Market Forecast
10.5 Europe Forecast by Countries
10.5.1 Germany Market Forecast
10.5.2 France Market Forecast
10.5.3 UK Market Forecast
10.5.4 Italy Market Forecast
10.5.5 Russia Market Forecast
10.5.6 Spain Market Forecast
10.6 Middle East and Africa Forecast by Countries
10.6.1 Egypt Market Forecast
10.6.2 South Africa Market Forecast
10.6.3 Israel Market Forecast
10.6.4 Turkey Market Forecast
10.6.5 GCC Countries Market Forecast
10.7 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Forecast by Type
10.8 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Forecast by Application
11 Key Players Analysis
11.1 Bristol-Myers Squibb
11.1.1 Company Details
11.1.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Product Offered
11.1.3 Bristol-Myers Squibb Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue, Gross Margin and Market Share (2017-2019)
11.1.4 Main Business Overview
11.1.5 Bristol-Myers Squibb News
11.2 FibroGen
11.2.1 Company Details
11.2.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Product Offered
11.2.3 FibroGen Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue, Gross Margin and Market Share (2017-2019)
11.2.4 Main Business Overview
11.2.5 FibroGen News
11.3 Italfarmaco
11.3.1 Company Details
11.3.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Product Offered
11.3.3 Italfarmaco Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue, Gross Margin and Market Share (2017-2019)
11.3.4 Main Business Overview
11.3.5 Italfarmaco News
11.4 Marathon Pharmaceuticals
11.4.1 Company Details
11.4.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Product Offered
11.4.3 Marathon Pharmaceuticals Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue, Gross Margin and Market Share (2017-2019)
11.4.4 Main Business Overview
11.4.5 Marathon Pharmaceuticals News
11.5 NS Pharma
11.5.1 Company Details
11.5.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Product Offered
11.5.3 NS Pharma Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue, Gross Margin and Market Share (2017-2019)
11.5.4 Main Business Overview
11.5.5 NS Pharma News
11.6 PTC Therapeutics
11.6.1 Company Details
11.6.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Product Offered
11.6.3 PTC Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue, Gross Margin and Market Share (2017-2019)
11.6.4 Main Business Overview
11.6.5 PTC Therapeutics News
11.7 Pfizer
11.7.1 Company Details
11.7.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Product Offered
11.7.3 Pfizer Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue, Gross Margin and Market Share (2017-2019)
11.7.4 Main Business Overview
11.7.5 Pfizer News
11.8 ReveraGen BioPharma
11.8.1 Company Details
11.8.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Product Offered
11.8.3 ReveraGen BioPharma Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue, Gross Margin and Market Share (2017-2019)
11.8.4 Main Business Overview
11.8.5 ReveraGen BioPharma News
11.9 Santhera Pharmaceuticals
11.9.1 Company Details
11.9.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Product Offered
11.9.3 Santhera Pharmaceuticals Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue, Gross Margin and Market Share (2017-2019)
11.9.4 Main Business Overview
11.9.5 Santhera Pharmaceuticals News
11.10 Sarepta Therapeutics
11.10.1 Company Details
11.10.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Product Offered
11.10.3 Sarepta Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue, Gross Margin and Market Share (2017-2019)
11.10.4 Main Business Overview
11.10.5 Sarepta Therapeutics News
12 Research Findings and Conclusion
